Issues in antiretroviral therapy: when to start?
Boyle, B.A.
Aids Reader 11(2): 66-70
2001
ISSN/ISBN: 1053-0894 PMID: 11279874 Document Number: 533296
Document emailed within 1 workday
Related Documents
Naidoo, K.; Baxter, C.; Abdool Karim, S.S. 2013: When to start antiretroviral therapy during tuberculosis treatment? Current Opinion in Infectious Diseases 26(1): 35-42Kumarasamy, N.; Patel, A.; Pujari, S. 2011: Antiretroviral therapy in Indian setting: when and what to start with, when and what to switch to? Indian Journal of Medical Research 134(6): 787-800
Walensky, R.P.; Wolf, L.L.; Wood, R.; Fofana, M.O.; Freedberg, K.A.; Martinson, N.A.; Paltiel, A.D.; Anglaret, X.; Weinstein, M.C.; Losina, E.; Messou, E.èn.; Seyler, C.; Touré, S.; Yazdanpanah, Y.; Kumarasamy, N.; Ganesh, J.; Ganesh, A.K.; Gray, G.; McIntyre, J.; Mohapi, L.; Cotich, K.; Goldie, S.; Horsburgh, C.R.; Kimmel, A.; Lipsitch, M.; McCormick, A.; Rydzak, C.; Seage, G.R.; Zhang, H.; Hsu, H.E.; Bassett, I.V.; Bender, M.A.; Chung, S.; Ciaranello, A.; Linas, B.P.; Lu, Z.; Morris, B.; Saxena, A.; Sloan, C.; Uhler, L.; Wang, B. 2009: When to start antiretroviral therapy in resource-limited settings Annals of Internal Medicine 151(3): 157-166
Rodger, A.J.; Sabin, C.A. 2016: How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection? Current Opinion in HIV and Aids 11(5): 487-491
Musisi, S.; Wagner, G.J.; Ghosh-Dastidar, B.; Nakasujja, N.; Dickens, A.; Okello, E. 2014: Depression and sexual risk behaviour among clients about to start HIV antiretroviral therapy in Uganda International Journal of Std and Aids 25(2): 130-137
Lesho, E.P.; Gey, D.C. 2003: Managing issues related to antiretroviral therapy American Family Physician 68(4): 675-686
Idemyor, V. 2001: HIV resistance and tolerability issues in antiretroviral therapy Journal of the National Medical Association 93(4): 151-153
Wagner, M.G. 1970: Research issues in child health. a head start research seminar. 3. Some socio-anthropologic and organizational issues Pediatrics 45(5): 868-873
Sharma, D.C. 2004: India's free antiretroviral programme gets off to slow start Lancet 363(9416): 1205
Alvi, Y.; Khalique, N.; Ahmad, A.; Khan, H.S.; Faizi, N. 2019: World Health Organization Dimensions of Adherence to Antiretroviral Therapy: a Study at Antiretroviral Therapy Centre, Aligarh Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive and Social Medicine 44(2): 118-124
Meintjes, G.; Black, J.; Conradie, F.; Dlamini, S.; Maartens, G.; Manzini, T.C.; Mathe, M.; Moorhouse, M.; Moosa, Y.; Nash, J.; Orrell, C.; Venter, F.; Wilson, D. 2015: Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy Southern African journal of HIV medicine 16(1): 428
Sharma, S.; Khadga, P.; Dhungana, G.P.; Chitrakar, U. 2013: Medication adherence to antiretroviral therapy among patients visiting antiretroviral therapy center at Tribhuvan University Teaching Hospital, Kathmandu Nepal Kathmandu University Medical Journal 11(41): 50-53
Muhamadi, L.; Nsabagasani, X.; Tumwesigye, M.Nazarius.; Wabwire-Mangen, F.; Ekström, A-Mia.; Peterson, S.; Pariyo, G. 2010: Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: policy challenges/bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral therapy (CD<350 cells/microL) in eastern Uganda Health Policy 97(2-3): 187-194
Mahy, M.; Lewden, C.; Brinkhof, M.W.G.; Dabis, F.; Tassie, J.-M.; Souteyrand, Y.; Stover, J. 2010: Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy Sexually Transmitted Infections 86(Suppl 2): Ii28-Ii34
Geffen, N.; Aagaard, P.; Corbelli, G.M.; Meulbroek, M.; Peavy, D.; Rappoport, C.; Schwarze, S.; Collins, S. 2015: Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial HIV Medicine 16(Suppl 1): 10-13
Mosam, A.; Shaik, F.; Uldrick, T.S.; Esterhuizen, T.; Friedland, G.H.; Scadden, D.T.; Aboobaker, J.; Coovadia, H.M. 2012: A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa Journal of Acquired Immune Deficiency Syndromes (1999) 60(2): 150-157
Mosam, A.; Shaik, F.; Uldrick, T.S.; Esterhuizen, T.; Friedland, G.H.; Scadden, D.T.; Aboobaker, J.; Coovadia, H.M. 2012: A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa Journal of Acquired Immune Deficiency Syndromes (1999) 60(2): 150-157
Zachariah, R.; Tayler-Smith, K.; Manzi, M.; Massaquoi, M.; Mwagomba, B.; van Griensven, J.; van Engelgem, I.; Arnould, L.; Schouten, E.J.; Chimbwandira, F.M.; Harries, A.D. 2011: Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes? Transactions of the Royal Society of Tropical Medicine and Hygiene 105(8): 421-430
Boyle, B.A. 2003: Issues in antiretroviral toxicity Aids Reader 13(10): 459 463
Boulle, A.; Orrel, C.; Kaplan, R.; Van Cutsem, G.; McNally, M.; Hilderbrand, K.; Myer, L.; Egger, M.; Coetzee, D.; Maartens, G.; Wood, R. 2007: Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort Antiviral therapy 12(5): 753-760